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CO-PRESCRIPTION OF GASTROPROTECTIVE AGENTS FOR
PATIENTS AT RISK OF NSNSAID-INDUCED
GASTROINTESTINAL HARM
Lister S1, Makinson G2, Koncz T2
1Pﬁzer Ltd,Tadworth, UK, 2Pﬁzer Limited,Tadworth, UK
OBJECTIVE: Patients prescribed non-selective (ns) NSAIDs are
at risk of gastrointestinal (GI) adverse events, hence the co-
prescription of gastroprotective agents (GPAs) as prophylactic
therapeutic options. Concerns over appropriate GPA co-
prescribing, especially for high-risk patients, prompted this
assessment of the level of GPA co-prescription for patients at GI
risk. METHODS: A primary care database (DIN-LINK), repre-
sentative of the UK, containing records of over 800,000 patients
was used. Patients with osteoarthritis and/or rheumatoid arthri-
tis who received nsNSAIDs and co-prescribed GPA between Sep-
tember 2003 and August 2005 were identiﬁed. Gastroprotection
level (%) was deﬁned by days on GPA within any three months
of nsNSAID use. Patients were grouped by level of gastropro-
tection. For each month, the percentage of patients at different
levels of gastroprotection was calculated and analysed according
to GI risk factors (NSAID use frequency, serious co-morbidity,
aspirin use, and previous GI adverse events). RESULTS: Approx-
imately 25,000 patients with nsNSAID prescriptions were 
identiﬁed. Of these, over half were frequent nsNSAID users (pre-
scribed nsNSAIDs for at least 75% of the observed period),
2.5% had previous GI adverse events, 12% were taking aspirin,
and over two thirds had serious co-morbidity. Of total nsNSAID
users, 18% used GPAs for the full period (100%); of frequent
nsNSAID users, 19.5%. By analysing patients with risk factors
and frequent nsNSAID use, the percentage of those using GPAs
for the full period was less than 40% with previous GI adverse
events, 30% for aspirin takers, and 22% with serious co-
morbidities. High, but not full (80–99%), GPA use was achieved
in similarly low numbers of patients with risk factors. CON-
CLUSION: Prescription data revealed frequent NSAID users
receive little co-prescribed GPAs. Presence of risk factors of
NSAID-induced GI risk did not increase GPA use, which may
increase GI-related hospitalisation risk.
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THE COST-UTILITY OF ADALIMUMAB (HUMIRA®) IN
PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN DENMARK
Aagren M1, Davies A2, Pang F3,Winding B4
1MUUSMANN Research & Consulting, Copenhagen, Denmark,
2United BioSource Corporation, London, England, 3Abbott
Laboratories Ltd, Maidenhead, Berks, UK, 4Abbott Laboratories,
Gentofte, Denmark
OBJECTIVES: Adalimumab is a human anti-TNF monoclonal
antibody for the treatment of RA. This study was designed to
assess the cost-effectiveness of adalimumab and the other bio-
logic agents compared with conventional disease-modifying anti-
rheumatic drugs (DMARDs) in patients with moderate/severe
RA. METHODS: A Monte-Carlo patient-level simulation was
developed to model patients’ Health Assessment Questionnaire
(HAQ) scores over a lifetime horizon. Efﬁcacy data were taken
from published literature and quality adjusted life years (QALYs)
were de-rived from HAQ-utility relationships. Both direct costs
(e.g. drug, administration, moni-toring, hospitalizations etc.) and
indirect costs were calculated for each patient. Discount-ing 
was applied at 5% for both costs and effectiveness. RESULTS:
Total discounted costs for adalimumab were 1,506,869 DKK,
while costs of DMARDs were 1,398,958 DKK. Effectiveness
amounted to 2.23 vs. 1.22 QALYs for adalimumab and
DMARD-therapy, respectively. Thus, the incremental cost-
effectiveness ratio (ICER) for adalimumab versus DMARD is
289,005 DKK per QALY. Inﬂiximab and etanercept generated
fewer QALYs than adalimumab, and had ICERs vs DMARDs,
of 321,723 DKK and 306,990 DKK per QALY, respectively.
CONCLUSIONS: This was the ﬁrst health economic analysis of
RA biologics in Denmark. The results suggest that adalimumab
is a cost-effective treatment option for patients with RA and is
more cost-effective than inﬂiximab and etanercept.
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ARE THEY MEASURABLE? A STUDY ON ELICITING INDIRECT
AND INTANGIBLE COSTS OF KNEE OSTEOARTHRITIS USING
HUMAN CAPITAL APPROACH AND WILLINGNESS-TO-PAY IN
MULTIETHNIC ASIAN POPULATION IN SINGAPORE
Xie F1,Thumboo J2, Fong KY3, Lo NN3,Yeo SJ3,Yang KY3, Li SC4
1National University of Singapore, Singapore, Singapore, 2Singapore
General Hospital, Singapore, Singapore, 3Singapore General Hospital,
Singapore, Singapore, Singapore, 4National University of Singapore,
Singapore, Singapore, Singapore
OBJECTIVES: To determine acceptability and feasibility of
human capital and willingness-to-pay approaches, estimate indi-
rect and intangible costs of knee OA using these approaches, and
identify factors potentially affecting these costs in Singapore.
METHODS: Data were collected through face-to-face interview
among knee OA patients. Human capital approach was used to
estimate indirect costs by multiplying: 1) days of absence from
work due to OA with average gross earning per capital per day
for working patients, or 2) productivity loss with the market
price of housekeeping and leisure activities for homemakers/
retirees. A closed-ended iterative bidding contingent valuation
method was used to elicit willingness-to-pay for a hypothetical
cure of OA as a proxy for intangible costs. Mann-Whitney U or
Kruskal-Wallis H tests were performed in univariate analysis,
and linear regression in multivariate analysis. RESULTS: Indi-
rect costs per year and intangible costs were estimated at
US$1008 and US$1200, accounting for 2.8% and 3.3% of
annual household income, respectively. The indirect costs were
signiﬁcantly higher for male or working patients, while intangi-
ble costs were higher for Chinese, working patients, patients with
higher income, or worse global wellbeing. CONCLUSION: This
study indicated that both human capital and WTP approaches
are acceptable and feasible methods in eliciting indirect and
intangible costs which are substantial for patients with knee OA
in Singapore. Most importantly, a congruence in the magnitude
of indirect costs relative to annual household income was
observed across countries, which implies that it may be possible
to provide a “standard reference range” of indirect costs for eco-
nomic evaluation for various diseases.
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BETTER HBA1C CONTROL WITH BOT VERSUS CT AVOIDS
LONG-TERM MICRO-VASCULAR COMPLICATIONS IN
PATIENTS WITH TYPE-2-DIABETES: MODEL SIMULATIONS
WITH THE DMM
Walzer S1, Huppertz E2, Mueller E1, Janka HU3
1Analytica International, Loerrach, Germany, 2Sanoﬁ-Aventis
Deutschland GmbH, Berlin, Germany, 3Zentralkrankenhaus Bremen-
Nord, Bremen, Germany
OBJECTIVES: Based on the clinical results of the LAPTOP study
(Diabetes Care 2005;28:254–9) a simulation with the Diabetes-
Mellitus-Model (version 3.2) was conducted. Long-term out-
